Saturday 17 October 2026
Export TAK’s income statement to Excel — free account
Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
19.67
0.22
+1.13%
Follow TAK
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 8 | 5 | 7 | 5 | 3 | 7 | 6 |
P/E ratio |
27.45 | 49.75 | 42.87 | 21.40 | 21.80 | 16.02 | 116.50 | 9.76 | 65.94 | 0.00 |
Altman Z-Score |
1.03 | 1.10 | 0.96 | 1.10 | 0.99 | 1.61 | 0.84 | 0.70 | 2.47 | 1.96 |
P/S ratio |
1.94 | 1.59 | 1.45 | 1.72 | 1.41 | 1.90 | 1.56 | 1.92 | 2.40 | 2.38 |
Altman Z″-Score (non-manufacturers) |
1.23 | 1.44 | 1.48 | 1.43 | 1.62 | 2.86 | 1.16 | 1.35 | 3.19 | 2.06 |
P/FCF ratio |
5.33 | 6.87 | 25.38 | 20.07 | 5.36 | 7.39 | 11.06 | 4.57 | 3.99 | 3.98 |
P/Operating CF |
9.22 | 8.47 | 21.76 | 21.51 | 13.10 | 15.64 | 27.71 | 17.05 | 22.30 | 22.26 |
Beneish M-Score |
(2.65) | (2.80) | (2.66) | (2.89) | (2.42) | (2.89) | (2.48) | (1.89) | (2.74) | (2.49) |
Dividend Safety Score |
25 | — | — | — | — | — | — | — | — | — |
P/B ratio |
1.17 | 0.95 | 0.85 | 1.09 | 0.89 | 1.17 | 1.09 | 1.76 | 2.02 | 2.13 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.94 |
EV/Sales |
2.83 | 2.55 | 2.48 | 2.67 | 2.38 | 3.03 | 2.91 | 2.29 | 2.79 | 2.51 |
EV/EBITDA |
10.59 | 11.90 | 11.22 | 9.30 | 8.14 | 3.17 | 14.00 | 7.49 | 5.92 | 0.00 |
EV/Operating CF |
5.34 | 7.15 | 14.76 | 10.99 | 7.57 | 9.60 | 14.30 | 4.36 | 3.85 | 3.50 |
EV/FCF |
7.77 | 11.06 | 43.28 | 31.18 | 9.06 | 11.82 | 20.62 | 5.44 | 4.63 | 4.21 |
Quick Ratio |
0.53 | 0.45 | 0.51 | 0.50 | 0.75 | 1.02 | 0.66 | 0.59 | 1.09 | 0.60 |
Current Ratio |
1.09 | 1.01 | 1.11 | 0.97 | 1.21 | 1.53 | 1.13 | 1.22 | 1.46 | 0.92 |
Net Debt/EBITDA |
5.84 | 3.72 | 4.64 | 3.32 | 3.32 | 1.19 | 6.49 | 10.53 | 1.44 | 2.03 |
Debt/Assets |
31.47% | 31.69% | 32.06% | 31.40% | 32.97% | 35.90% | 39.73% | 41.46% | 24.00% | 26.28% |
Debt/Equity |
0.66 | 0.65 | 0.67 | 0.69 | 0.76 | 0.90 | 1.08 | 1.11 | 0.49 | 0.59 |
Asset Turnover |
0.30 | 0.31 | 0.28 | 0.27 | 0.27 | 0.25 | 0.25 | 0.23 | 0.41 | 0.45 |
Operating CF/Net income |
(6.83) | 9.80 | 4.97 | 3.08 | 4.88 | 2.69 | 15.14 | 3.01 | 2.02 | 2.27 |
Capex/Depreciation |
(0.57) | (0.50) | (0.65) | (0.95) | (0.32) | (0.34) | (0.35) | (0.31) | (0.69) | (0.49) |
Interest Coverage |
0.02 | 1.63 | 0.97 | 2.89 | 2.77 | 10.05 | 0.61 | 2.46 | 7.57 | 6.70 |
| (2.12%) | 1.48% | 2.05% | 4.81% | 4.13% | 7.67% | 0.90% | 3.04% | 9.27% | 6.14% | |
| (1.02%) | 0.72% | 0.96% | 2.13% | 1.72% | 2.95% | 0.34% | 1.21% | 4.34% | 2.96% | |
ROIC |
0.03% | 1.94% | 1.15% | 3.01% | 3.15% | 17.72% | 0.68% | 1.26% | 5.75% | 3.58% |
Return on Tangible Assets |
(6.41%) | 5.44% | 6.45% | 19.72% | 11.33% | 15.71% | 2.63% | 5.88% | 21.28% | 27.06% |
Average Days of Receivables |
70.99 | 57.78 | 59.72 | 61.78 | 74.08 | 92.76 | 87.05 | 130.38 | 88.40 | 93.73 |
Research and Development Expense of Revenue |
15.00% | 15.94% | 17.12% | 15.73% | 14.74% | 14.25% | 14.96% | 17.56% | 18.38% | 18.03% |
Selling, General and Administrative Expense of Revenue |
24.06% | 24.11% | 24.72% | 24.76% | 24.83% | 27.38% | 29.31% | 34.22% | 35.48% | 35.74% |
Intangible Assets out of Total Assets |
0.59 | 0.63 | 0.64 | 0.65 | 0.62 | 0.62 | 0.64 | 0.65 | 0.50 | 0.48 |
Share Based Compensation of Revenue |
1.62% | 1.59% | 1.66% | 1.51% | 1.22% | 1.18% | 0.88% | 0.96% | 1.05% | 0.00% |
Graham Net Nets |
(0.52) | (0.70) | (0.85) | (0.75) | (0.97) | (0.83) | (1.09) | (0.29) | (0.25) | (0.12) |
Graham Number |
15.01 | 15.16 | 10.73 | 16.20 | 15.46 | 19.99 | 6.40 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
3.64% | 2.01% | 2.33% | 4.67% | 4.59% | 6.24% | 0.86% | 10.25% | 1.52% | (1.61%) |
Free Cash Flow Yield |
18.77% | 14.56% | 3.94% | 4.98% | 18.66% | 13.53% | 9.04% | 21.88% | 25.05% | 25.10% |
Revenue per Share |
9.44 | 9.58 | 9.40 | 9.60 | 10.16 | 9.62 | 9.72 | 9.82 | 10.20 | 10.31 |
Operating CF per Share |
2.18 | 2.21 | 1.58 | 2.33 | 3.20 | 3.04 | 1.98 | 1.54 | 2.18 | 1.56 |
Capex per Share |
(0.86) | (0.79) | (1.04) | (1.51) | (0.52) | (0.57) | (0.61) | (0.39) | (0.72) | (0.65) |
Free Cash Flow per Share |
1.33 | 1.42 | 0.54 | 0.82 | 2.67 | 2.47 | 1.37 | 1.15 | 1.46 | 0.91 |
Cash per Share |
1.33 | 0.85 | 1.04 | 1.32 | 2.49 | 3.02 | 1.93 | 3.39 | 2.16 | 2.24 |
Shareholders Equity per Share |
15.57 | 14.50 | 16.04 | 15.15 | 16.18 | 15.58 | 13.97 | 24.17 | 11.63 | 11.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
15.57 | 14.50 | 16.04 | 15.15 | 16.18 | 15.58 | 13.97 | 24.17 | 11.63 | 11.60 |
Free Cash Flow |
4,179.29 | 4,472.39 | 1,685.12 | 2,548.78 | 8,356.06 | 7,716.61 | 4,274.50 | 2,205.74 | 2,273.01 | 1,416.75 |
Working Capital |
1,705.63 | 96.83 | 1,693.79 | (621.48) | 3,986.41 | 8,833.34 | 2,700.51 | 4,857.54 | 3,071.69 | (980.49) |
Capital Expenditures |
(2,694.15) | (2,505.01) | (3,257.66) | (4,682.18) | (1,639.58) | (1,786.14) | (1,887.21) | (750.57) | (1,127.67) | (1,013.92) |
Net Current Asset Value |
(32,936.34) | (31,621.74) | (36,405.84) | (38,517.90) | (43,617.60) | (47,208.90) | (51,742.43) | (50,922.69) | (9,092.22) | (10,659.25) |
EV/EBIT |
28.91 | 57.30 | 49.37 | 21.90 | 18.45 | 3.88 | 95.40 | 7.49 | 5.92 | 0.00 |
Capex to Sales |
0.09 | 0.08 | 0.11 | 0.16 | 0.05 | 0.06 | 0.06 | 0.04 | 0.07 | 0.06 |
Price to Operating Income |
19.81 | 35.59 | 28.96 | 14.09 | 10.92 | 2.43 | 51.18 | 6.29 | 5.10 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.39 | 0.37 | 0.39 | 0.37 | 0.38 | 0.42 | 0.21 | 0.34 | 0.42 |
Cash ROIC |
4.89% | 5.72% | 1.94% | 3.05% | 8.61% | 7.59% | 4.44% | 2.11% | 7.48% | 4.39% |
Accounts Receivable Turnover |
5.63 | 6.30 | 5.97 | 5.19 | 4.51 | 4.05 | 4.34 | 3.56 | 3.99 | 4.18 |
Accounts Payable Turnover |
3.25 | 3.02 | 2.29 | 1.96 | 2.52 | (3.03) | 3.41 | 2.32 | 2.03 | 2.72 |
Inventory Turnover |
1.20 | 1.27 | 1.26 | 1.24 | 1.34 | (1.33) | 1.26 | 1.10 | 2.22 | 2.47 |
Average Days of Payables |
114.11 | 109.84 | 140.08 | 190.48 | 170.26 | (126.22) | 106.78 | 181.14 | 176.83 | 157.18 |
Days of Inventory on Hand |
324.36 | 281.18 | 309.53 | 289.42 | 281.35 | (276.74) | 254.42 | 545.96 | 156.73 | 147.82 |
Average Receivables |
5,285.29 | 4,800.09 | 4,929.02 | 5,745.74 | 7,043.23 | 7,430.39 | 6,981.67 | 5,300.60 | 3,997.78 | 3,855.09 |
Average Payables |
3,190.72 | 3,458.23 | 4,291.11 | 4,699.68 | 3,913.56 | 3,082.59 | 2,939.83 | 2,554.44 | 2,200.06 | 1,911.92 |
Average Inventory |
8,626.10 | 8,191.30 | 7,823.94 | 7,446.48 | 7,339.83 | 7,037.40 | 7,934.50 | 5,398.60 | 2,010.52 | 2,106.41 |
Average Assets |
98,207.49 | 99,144.89 | 103,769.05 | 110,285.90 | 119,330.00 | 119,664.85 | 121,402.50 | 80,904.54 | 38,733.47 | 36,124.34 |
Average Common Equity |
47,409.88 | 47,984.05 | 48,607.60 | 48,803.96 | 49,624.41 | 46,079.17 | 44,982.58 | 32,314.49 | 18,141.03 | 17,409.18 |
Columns are period end dates